Supreme Court Allows Continued Access to Abortion Medication During Lawsuit

The U.S. Supreme Court on Thursday ruled that access to mifepristone, a key medication for abortion, can continue across the country while a lawsuit against its availability is ongoing. The ruling, which lasts indefinitely, was issued as part of a series of decisions related to legal challenges against the drug’s use via telehealth.

The case stems from a lawsuit filed last year by Louisiana against the Food and Drug Administration. The state argued that allowing telehealth prescriptions of mifepristone undermines its abortion ban. Since the Dobbs decision in 2022 overturned the constitutional right to an abortion, 13 states have implemented total bans, though overall abortions have increased nationwide.

Over the past two weeks, federal courts have issued conflicting rulings on access to mifepristone. A federal judge in Louisiana initially restricted telemedicine prescriptions on May 1. The Supreme Court temporarily halted that ruling on May 4, allowing prescriptions to continue. The court then extended full access through Thursday before making the current decision.

Legal experts said the ruling signals that the Supreme Court sees merit in the manufacturers’ argument that requiring in-person visits is unnecessary. Mary Ziegler, a law professor at UC Davis, noted that the decision indicates the court recognizes the manufacturers have a strong case, even if it did not specify the reasoning.

For states like Mississippi, where medication accounts for all abortions under a near-total ban, the ruling offers significant relief. According to research from KFF, between 200 and 600 Mississippians use these drugs each month to terminate pregnancies. Kelly Baden of the Guttmacher Institute called the ruling a needed pause but warned that legal battles and threats to abortion access will persist.

Source: Original Article